GlassScriptPhysician profile
Michael J Snedeker
NPI 1780954206
$8,488.54
in general payments reported to CMS, 2019-2025
25 companies · $1,780 in 2025
The $1,780 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $1,025 · 2023: $1,742 · 2024: $2,973 · 2025: $1,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,991 · Consulting Fee: $1,063 · Education: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,991.09 |
| Consulting Fee | $1,062.50 |
| Education | $441.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,688.99 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,709.56 | 2021-2025 | |
| Ucb, INC. | $529.45 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $468.56 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $375.74 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $361.34 | 2021-2025 | |
| Leo Pharma INC. | $334.64 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $302.54 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $252.17 | 2021-2025 | |
| Incyte Corporation | $249.37 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $240.36 | 2022-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $205.48 | 2021-2025 | Nemluvio, Twyneo, Aklief |
| Arcutis Biotherapeutics, INC. | $202.06 | 2023-2025 | Zoryve |
| Pfizer INC. | $125.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.69 | 2023-2024 | Spevigo, Cyltezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $80.06 | 2023-2024 | Vtama |
| Amgen INC. | $62.62 | 2022-2024 | Otezla |
| Organon LLC | $52.94 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $38.01 | 2023-2024 | Ycanth |
| Krystal Biotech INC | $25.03 | 2023 | Vyjuvek |
| Almirall LLC | $22.16 | 2023 | Klisyri |
| Kyowa Kirin, INC. | $21.50 | 2025 | |
| Stemline Therapeutics INC. | $15.72 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.32 | 2021 | |
| Biofrontera INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snedeker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.